CleanSpark (CLSK) stock jumps 14% as bitcoin steadies near $90,000 — what traders watch next
3 January 2026
1 min read

CleanSpark (CLSK) stock jumps 14% as bitcoin steadies near $90,000 — what traders watch next

NEW YORK, January 3, 2026, 10:40 ET — Market closed

  • CleanSpark closed up 14% at $11.55 in Friday’s session, lifting with other U.S.-listed bitcoin miners.
  • Bitcoin held near the $90,000 mark late Friday as broader markets ended mixed.
  • Focus shifts to next week’s U.S. data slate and CleanSpark’s next earnings window in early February.

CleanSpark shares surged 14.0% to close at $11.55 on Friday. The stock traded between $10.20 and $11.61 and changed hands in about 22.2 million shares.

The bitcoin miner’s shares often swing harder than bitcoin itself because its revenue is tied to the token’s price while many operating costs, such as power and equipment, don’t move as quickly.

That leverage matters at the start of the year, when portfolio rebalancing and shifts in risk appetite can amplify moves in crypto-linked stocks.

Markets are also looking ahead to a heavy run of U.S. economic data next week after last year’s lengthy shutdown delayed releases, with Friday’s U.S. payrolls report a key test for interest-rate expectations. 1

Bitcoin gained about 1.7% to $89,789.87 late Friday, Reuters reported. “Value is outperforming growth and AI infrastructure is up,” said Jed Ellerbroek, portfolio manager at Argent Capital. 2

Other U.S.-listed miners climbed in sympathy. Marathon Digital rose about 10% and Riot Platforms gained about 12% on Friday.

Bitcoin miners earn bitcoin for validating transactions on the network; a higher bitcoin price increases the dollar value of those rewards.

Investors also track mining difficulty, which adjusts how hard it is to win those rewards, and power prices, which can make or break margins.

CleanSpark has been pitching itself as more than a pure-play miner as data-center leading themes bleed into the sector. In an Oct. 29 SEC filing, the company said it secured rights to about 271 acres in Texas and signed long-term power agreements totaling 285 megawatts to support a data-center campus aimed at AI, cloud and enterprise workloads.

In its most recent fiscal-year results, CleanSpark reported $766.3 million in revenue and pointed to contracted power growth as a base for expanding into artificial intelligence and high-performance computing, a press release showed.

Analyst targets still imply large upside from Friday’s close. MarketBeat data shows an average price target of $23.20 for CleanSpark, though those targets were set before this week’s jump.

For now, traders are treating the stock as a fast-moving read-through on bitcoin’s direction and on whether the rally in crypto-linked equities holds as regular liquidity returns.

Before Monday’s open, weekend moves in bitcoin will be the first catalyst for premarket pricing, with next week’s U.S. data calendar likely to shape broader risk appetite.

CleanSpark’s next scheduled catalyst is earnings. MarketBeat estimates the company will report on Feb. 5, and investors will be looking for updates on hashrate — the computing power used to mine bitcoin — and spending tied to new sites and data-center development.

Stock Market Today

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Amazon stock tumbles on $200 billion AI spend plan — what to know before Monday

Amazon stock tumbles on $200 billion AI spend plan — what to know before Monday

7 February 2026
Amazon shares fell 5.6% to $210.32 on Friday after the company projected about $200 billion in 2026 capital expenditures, triggering investor concern over AI spending. The stock had already dropped 11.5% after-hours Thursday. Amazon forecast Q1 net sales of $173.5–$178.5 billion and operating income of $16.5–$21.5 billion. Analyst Gil Luria downgraded Amazon, citing rising investment as its cloud lead narrows.
Boeing stock jumps nearly 5% to start 2026 — here’s what traders watch next
Previous Story

Boeing stock jumps nearly 5% to start 2026 — here’s what traders watch next

Salesforce stock slides 4% as 2026 opens — here’s what’s driving CRM and what investors watch next
Next Story

Salesforce stock slides 4% as 2026 opens — here’s what’s driving CRM and what investors watch next

Go toTop